Endobronchial Ultrasound Biopsy Market Size (2024 - 2029)

The endobronchial ultrasound biopsy market is expected to experience growth over the forecast period, driven by the increasing prevalence of respiratory disorders such as chronic obstructive pulmonary disease, tuberculosis, and lung cancer. The market's expansion is supported by the recovery from COVID-19 impacts and the introduction of technologically advanced products by key players. Strategic initiatives, including product launches and partnerships, are contributing to the market's development. However, challenges such as high equipment costs and limited reimbursement policies in developing regions may hinder market growth.

Market Size of Endobronchial Ultrasound Biopsy Industry

Single User License

$4750

Team License

$5250

Corporate License

$8750

Book before:
Endobronchial Ultrasound Biopsy Market Summary
Study Period 2021 - 2029
Base Year For Estimation 2023
CAGR (2024 - 2029) 4.36 %
Fastest Growing Market Asia Pacific
Largest Market North America
Market Concentration Low

Major Players

Endobronchial Ultrasound Biopsy Market Major Players

*Disclaimer: Major Players sorted in no particular order

Need a report that reflects how COVID-19 has impacted this market and its growth?

Single User License

$4750

Team License

$5250

Corporate License

$8750

Book before:

Endobronchial Ultrasound Biopsy Market Analysis

The Endobronchial Ultrasound Biopsy Market is expected to register a CAGR of 4.36% during the forecast period.

Respiratory disorders such as chronic obstructive pulmonary disorder (COPD), tuberculosis, and lung and bronchus cancer use endobronchial ultrasound biopsy to obtain tissue or fluid samples from the lungs and surrounding lymph nodes without conventional surgery to diagnose and detect the severity of diseases. For instance, according to 2024 statistics published by the American Lung Association, an estimated 11.7 million, or 4.6% of the adult population, in the United States were given a COPD diagnosis in 2022. This translates to a large patient pool potentially requiring diagnosis. Similarly, according to the Australian Bureau of Statistics 2022 update, adults aged 65 years and above are significantly more likely to have COPD, with roughly one in fourteen (7.0%) being diagnosed. Therefore, the rising prevalence of respiratory disorders is a potential driver for the endobronchial ultrasound biopsy market.

Additionally, while smoking is the leading cause of COPD, particularly in high-income countries, household air pollution is another significant risk factor in low- and middle-income countries (LMICs). This is especially concerning as smoking rates are on the rise in LMICs, suggesting a potential explosion of COPD cases in the coming decades. As the global COPD burden grows, particularly in LMICs, the demand for accurate and early diagnosis tools like EBUS is expected to rise in the near future. This overall growth in respiratory illnesses is likely to drive up the demand for accurate and minimally invasive diagnostic tools like EBUS during the forecast period.

Furthermore, according to the World Health Organization Report 2023, an estimated global total of 10.6 million people (ranging from 9.9 to 11.4 million) contracted TB, translating to 133 incident cases per 100,000 individuals. The majority of TB cases in 2022 were concentrated in the WHO regions of Southeast Asia (46%), Africa (23%), and the Western Pacific (18%), with smaller proportions in the Eastern Mediterranean (8.1%), the Americas (3.1%), and Europe (2.2%) in 2022. While TB primarily affects the lungs, it can also spread to other parts of the body (extrapulmonary TB). EBUS can be a valuable tool in diagnosing extrapulmonary TB cases by guiding needle biopsies of lymph nodes or other affected tissues. The number of tuberculosis (TB) cases is expected to rise, further fueling the demand for endobronchial ultrasound biopsy for this specific region.

Therefore, owing to the aforementioned factors, such as the high burden of respiratory diseases and increasing demand for minimally invasive procedures, the market is anticipated to witness growth during the forecast period. However, the high cost of equipment and lack of reimbursement policies in developing countries are likely to restrain the market's growth.

Endobronchial Ultrasound Biopsy Industry Segmentation

As per the scope of the report, endobronchial ultrasound is a technique for biopsy and visualization of the structure around the tracheobronchial tree.

The endobronchial ultrasound biopsy market is segmented by product, application, and geography. By product, the market is segmented into biopsy forceps, cytology brushes, biopsy needles, transbronchial aspiration needles, spray catheters, and other products. By application, the market is segmented into cancer diagnosis, infection diagnosis, and other applications. By geography, the market is segmented into North America, Europe, Asia-Pacific, Middle East and Africa, and South America. The report offers the value (USD) for the above segments.

By Product
Biopsy Forceps
Cytology Brushes
Biopsy Needles
Transbronchial Aspiration Needles
Spray Catheters
Other Products
By Application
Cancer Diagnosis
Infection Diagnosis
Other Applications
Geography
North America
United States
Canada
Mexico
Europe
Germany
United Kingdom
France
Italy
Spain
Rest of Europe
Asia-Pacific
China
Japan
India
Australia
South Korea
Rest of Asia-Pacific
Middle East and Africa
GCC
South Africa
Rest of Middle East and Africa
South America
Brazil
Argentina
Rest of South America
Need A Different Region Or Segment?
Customize Now

Endobronchial Ultrasound Biopsy Market Size Summary

The endobronchial ultrasound biopsy market is expected to experience steady growth over the forecast period, driven by the increasing prevalence of respiratory disorders such as chronic obstructive pulmonary disease (COPD), tuberculosis, and lung cancer. These conditions necessitate the use of endobronchial ultrasound biopsy for minimally invasive diagnosis and staging, which is gaining traction due to its effectiveness and reduced recovery time compared to traditional surgical methods. The market's recovery from the initial setbacks caused by COVID-19 is attributed to the lifting of restrictions and the resumption of elective procedures. Strategic initiatives by key players, including product launches and technological advancements, are further propelling market expansion. However, challenges such as high equipment costs and limited reimbursement policies in developing regions may hinder growth.

North America is anticipated to lead the market, supported by a high incidence of lung cancer and respiratory diseases, coupled with significant research and development investments in diagnostics. The region's concentration of market players and government support for innovative device development create a conducive environment for market growth. The fragmented nature of the market, with numerous global and local players like Medtronic, Boston Scientific, and Olympus, fosters competition and innovation. As the demand for minimally invasive procedures rises and clinical trials yield positive results, the endobronchial ultrasound biopsy market is poised for continued growth, with North America playing a pivotal role in its expansion.

Explore More

Endobronchial Ultrasound Biopsy Market Size - Table of Contents

  1. 1. MARKET DYNAMICS

    1. 1.1 Market Overview

    2. 1.2 Market Drivers

      1. 1.2.1 Rising Geriatric Population

      2. 1.2.2 Increasing Prevalence of Respiratory Disorders

      3. 1.2.3 Increasing demand for Minimally Invasive Procedures

    3. 1.3 Market Restraints

      1. 1.3.1 High Cost of Equipment

      2. 1.3.2 Lack Reimbursement Policies in Developing Countries

    4. 1.4 Porter's Five Forces Analysis

      1. 1.4.1 Threat of New Entrants

      2. 1.4.2 Bargaining Power of Buyers/Consumers

      3. 1.4.3 Bargaining Power of Suppliers

      4. 1.4.4 Threat of Substitute Products

      5. 1.4.5 Intensity of Competitive Rivalry

  2. 2. MARKET SEGMENTATION (Market Size by Value - USD)

    1. 2.1 By Product

      1. 2.1.1 Biopsy Forceps

      2. 2.1.2 Cytology Brushes

      3. 2.1.3 Biopsy Needles

      4. 2.1.4 Transbronchial Aspiration Needles

      5. 2.1.5 Spray Catheters

      6. 2.1.6 Other Products

    2. 2.2 By Application

      1. 2.2.1 Cancer Diagnosis

      2. 2.2.2 Infection Diagnosis

      3. 2.2.3 Other Applications

    3. 2.3 Geography

      1. 2.3.1 North America

        1. 2.3.1.1 United States

        2. 2.3.1.2 Canada

        3. 2.3.1.3 Mexico

      2. 2.3.2 Europe

        1. 2.3.2.1 Germany

        2. 2.3.2.2 United Kingdom

        3. 2.3.2.3 France

        4. 2.3.2.4 Italy

        5. 2.3.2.5 Spain

        6. 2.3.2.6 Rest of Europe

      3. 2.3.3 Asia-Pacific

        1. 2.3.3.1 China

        2. 2.3.3.2 Japan

        3. 2.3.3.3 India

        4. 2.3.3.4 Australia

        5. 2.3.3.5 South Korea

        6. 2.3.3.6 Rest of Asia-Pacific

      4. 2.3.4 Middle East and Africa

        1. 2.3.4.1 GCC

        2. 2.3.4.2 South Africa

        3. 2.3.4.3 Rest of Middle East and Africa

      5. 2.3.5 South America

        1. 2.3.5.1 Brazil

        2. 2.3.5.2 Argentina

        3. 2.3.5.3 Rest of South America

Endobronchial Ultrasound Biopsy Market Size FAQs

The Endobronchial Ultrasound Biopsy Market is projected to register a CAGR of 4.36% during the forecast period (2024-2029)

Boston Scientific Corporation, CONMED Corporation, Olympus Corporation, Medtronic and Cook Group are the major companies operating in the Endobronchial Ultrasound Biopsy Market.

Endobronchial Ultrasound Biopsy Market Size & Share Analysis - Growth Trends & Forecasts (2024 - 2029)